vigabatrine

Action and Spectrum

Drug Interaction

Adverse Reaction

>10%: 

Weight gain 

Fatigue  

Somnolence  

Headache  

Weight gain, adults  

Dizziness  

Convulsion  

Hyperactivity 

1-10%: 

Nasopharyngitis  

Weight increased  

Upper respiratory tract infection  

Visual field defect  

Depression  

Tremor  

Nystagmus  

Nausea  

Diarrhea  

Memory impairment  

Insomnia  

Irritability  

Coordination abnormal  

Vision blurred  

Diplopia  

Vomiting  

Influenza  

Pyrexia 

Rash 

Black Box Warning

Contraindication / Caution

Vigabatrin is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients. 

Pregnancy / Lactation

Pregnancy consideration:  

No studies reported of usage of vigabatrin in pregnant women 

Breastfeeding warnings:  

Vigabatrin is excreted in breast milk. Hence the drug should be used with caution during breastfeeding. 

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: No evidence shows the risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women.    
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a human product; Pregnant women must take care of the potential risks. 
• Category D: There is adequate data available with evidence of human fetal risk from various platforms. However, despite potential dangers may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh the risks over the benefits. The drug is not for pregnant women. 
• Category N: No data is available for the drug under this category. 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name:  vigabatrin 

Pronounced: viga-bat-rin 

Why do we use vigabatrin? 

Vigabatrin treats partial seizures and infantile spasms.